Reduced JAK Inhibitor Dosing May Not Compromise RA Outcomes
A study found that patients with rheumatoid arthritis who started on reduced doses of JAK inhibitors maintained similar treatment persistence and disease control as those on standard doses over 24 months. The research included 1,135 patients with preserved kidney function and showed no significant differences in drug retention between the two dosing groups. However, patients with more poor prognostic factors had a lower risk of discontinuation when on standard doses compared to reduced doses.
- ▪The study involved 1,135 patients with rheumatoid arthritis from multiple Japanese centers.
- ▪Patients were categorized based on whether they received standard or reduced doses of JAK inhibitors.
- ▪24-month drug retention rates were comparable between the reduced-dose and standard-dose groups for patients with preserved renal function.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Patients with rheumatoid arthritis (RA) and preserved kidney function who started reduced doses of JAK inhibitors had treatment persistence and disease control that were similar to those in patients who started standard doses over 24 months of follow‑up.METHODOLOGY:Researchers conducted an observational cohort study to compare 24‑month treatment persistence between standard‑dose and reduced‑dose JAK inhibitors in patients with RA, with a primary focus on those with preserved renal function.They included 1135 patients from a registry (ANSWER) who started treatment with JAK inhibitors at multiple Japanese centers between March 2013 and October 2025.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
